Compare Funko Inc (FNKO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Funko Inc trades at $5.98 (market cap $332.33M), while Regeneron Pharmaceuticals Inc trades at $798.62 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 246.9× Funko Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Funko Inc pays none. Which is the better fit depends on your goals.
| FNKO | REGN | |
|---|---|---|
Market Cap | $332.33M | $82.06B |
Sector | Consumer Staples | Health |
52-Week High | $6.35 | $812.27 |
52-Week Low | $2.65 | $555.51 |
Enterprise Value | $552.98M | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $5.86, down 5.33% on the day, amid mixed signals. The stock shows a bullish technical trend with strong moving average support, while oscillators are neutral. Fundamentally, revenue declined to $908.21M in 2025 with a net loss of $67.36M, though recent quarters have beaten EPS estimates. The company maintains a low P/S of 0.35 and appointed a new Chief Commercial Officer in August 2026 to drive growth.
Outlook is cautiously optimistic with improving EBITDA guidance and analyst buy ratings, but risks include persistent net losses, high debt levels, and competitive pressures in the collectibles market. The stock's valuation discount offers potential if profitability strengthens.
Regeneron Pharmaceuticals (REGN) trades at $794.71, down 1.65% on the day, with strong fundamentals including a P/E of 19.72 and net income margin of 27.86%. The stock is in a bullish technical trend, supported by moving averages, though RSI levels indicate overbought conditions. Recent quarterly EPS results have consistently beaten expectations, and the company maintains robust cash flow from operations of $4.98 billion in 2025. However, multiple class action lawsuits related to clinical trial disclosures present a near-term headwind.
The outlook remains positive due to earnings strength and analyst consensus, but legal risks and high valuation multiples warrant caution. Upside is supported by product growth in Eylea HD and Dupixent, while downside risks include litigation outcomes and potential regulatory scrutiny. The stock trades above the consensus price target of $756.93, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
